2018 | |
---|---|
Criterium: | Position: |
Overall Score: | > 1000 |
Total Project Funding per Partner: | > 1000 |
Total Number of Projects: | > 1000 |
Networking Rank (Reputation): | > 1000 |
2015 | |
Criterium: | Position: |
Overall Score: | > 1000 |
Networking Rank (Reputation): | > 1000 |
Total number of projects: 4
As coordinator: 0
As participant: 4
Sole participant: 0
Coordinator / Participant Ratio: 0*
Total project funding [€]: | Projects [No]: | |||||
---|---|---|---|---|---|---|
Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
2018 | 0 | 12.748.676 | 399.875 | 2 | ||
2015 | 0 | 11.419.487 | 647.619 | 2 |
Total number of partners: 46
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 46
Frequent / Rare Partner Ratio: 0
Start date | Project | acronym | role | funding | partners |
---|---|---|---|---|---|
2018-01-01 | Adeno-Associated Virus Vector-Mediated Liver Gene Therapy for Crigler-Najjar Syndrome | CureCN | participant | 6.249.104 | 11 |
2018-01-01 | Testing the value of a novel strategic approach and its cost efficacy to improve the poor outcomes in Cardiogenic Shock | EURO SHOCK | participant | 6.499.572 | 16 |
2015-05-01 | A multi-center randomized, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease | BETA3_LVH | participant | 5.425.113 | 12 |
2015-05-01 | Novel Stromal Cell Therapy for Diabetic Kidney Disease | NEPHSTROM | participant | 5.994.374 | 11 |